{"filing":{"accession_number":"0001104659-26-078323","cik":"0001069899","ticker":"PAHC","company_name":"PHIBRO ANIMAL HEALTH CORP","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"tm2619111d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926078323/tm2619111d1_8k.htm"},"events":[{"id":14349,"run_id":12774,"accession_number":"0001104659-26-078323","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Daniel Bendheim's appointment to Chief Executive Officer and President effective July 1, 2026 is the principal disclosed action. While the filing also details compensatory arrangements (employment agreement with $850,000 base salary, bonus, RSU grants), the core event is the executive appointment to the top leadership role. This is material to investors as CEO appointments significantly affect company direction and governance.","company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11744,"accession_number":"0001104659-26-078323","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Daniel Bendheim's appointment to Chief Executive Officer and President effective July 1, 2026 is the principal disclosed action. While the filing also details compensatory arrangements (employment agreement with $850,000 base salary, bonus, RSU grants), the core event is the executive appointment to the top leadership role. This is material to investors as CEO appointments significantly affect company direction and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T21:08:36.444144+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11744,"accession_number":"0001104659-26-078323","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Daniel Bendheim's appointment to Chief Executive Officer and President effective July 1, 2026 is the principal disclosed action. While the filing also details compensatory arrangements (employment agreement with $850,000 base salary, bonus, RSU grants), the core event is the executive appointment to the top leadership role. This is material to investors as CEO appointments significantly affect company direction and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T21:08:36.444144+00:00","company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","filing_date":"2026-06-26"}]}